Genomic Landscape and Clinical Features of Advanced Thyroid Carcinoma: A National Database Study in Japan
Authors' conclusion
Genetic abnormalities with treatment options were found in 62.7% of advanced thyroid carcinomas. TP53 abnormality was an independent poor prognostic factor for overall survival in differentiated thyroid carcinoma. The time to treatment failure for lenvatinib was not different based on genetic profile.
Study context
- Population
- Advanced thyroid carcinoma requiring drug therapy, national database in Japan; ATC 23.6%, PDTC 10.0%, DTC 66.4%of 53,543 in database
- Participants
- 552 participants
- Outcome
- Treatment period (time to treatment failure) and overall survival by genetic alteration
Methodological detailsnational database
- National database
Main finding
As reported in the abstract
Genomic profile and prognosis
- TERT promoter alterations
- 66.3%
- BRAF alterations
- 56.7%
- TP53 alterations
- 32.2%
- BRAF V600E
- 55.0%
- RAS
- 18.5%
- RET fusion
- 4.7%
- NTRK fusion
- 1.6%
- ALK fusion
- 0.4%
- DTC and PDTC: TP53 alterations independently predicted worse OS, HR
- 2.205 (95% CI 1.135-4.283)
Observational data: associations, not effects.
Original publication
Genomic Landscape and Clinical Features of Advanced Thyroid Carcinoma: A National Database Study in Japan. J Clin Endocrinol Metab. Published 17 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →